Vmbook Online ordering

Neogenomics Inc

Neogenomics Inc (NEO) is a public company that specializes in cancer diagnostics and pharmaceutical services. The company operates in two segments: Clinical Genomics and Pharmaceutical Services.

The Clinical Genomics segment provides diagnostic testing services to pathologists, clinicians, and hospitals, with a focus on cancer-related testing. This segment generates revenue through a combination of fee-for-service and subscription-based models.

The Pharmaceutical Services segment provides testing and support services to pharmaceutical and biotechnology companies, with a focus on oncology and neuroscience. This segment generates revenue through a combination of fee-for-service and contract research models.

In terms of financial performance, Neogenomics has generally been growing its revenue and earnings in recent years. The company's revenue has increased from $203.1 million in 2017 to $345.0 million in 2020, representing a compound annual growth rate (CAGR) of 21.5%. The company's net income has also grown from $10.2 million in 2017 to $25.8 million in 2020, representing a CAGR of 35.6%.

Neogenomics has also been increasing its earnings per share (EPS) over the past several years. The company's EPS grew from $0.53 in 2017 to $1.07 in 2020, representing a CAGR of 34.5%.

Neogenomics has a strong balance sheet with a conservative debt-to-equity ratio of 0.32 as of December 31, 2020. The company has $141.7 million in cash and cash equivalents, which provides it with a strong liquidity position.

However, it's important to note that past performance is not a guarantee of future results, and investors should always conduct their own research and due diligence before making investment decisions.